- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Survey Finds 2020 Elections May Impact Healthcare Investment Outlook
KPMG, a firm that provides business solutions and audit, tax, and advisory services, released the results of its Health Care & Life Sciences Investment Outlook survey. The survey finds that healthcare and life sciences investment professionals believe the volume of deals will grow in most sectors in 2020 compared to last year. However, they also believe that upcoming elections could impact the investment outlook.
Nearly half of investors surveyed anticipate that the 2020 election could have a potentially negative impact on investment activity in healthcare (48%) and life sciences (47%). Only 19% of investors surveyed expect the election leading to increased investment in healthcare, and 13% of investors surveyed said the same for life sciences.
Read the full report here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
